Annals of Oncology 10:1175-1179, 1999
© 1999 European Society for Medical Oncology
research-article |
Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study
1Ottawa Regional Cancer Centre Ottawa, Ontario
2Saint John Regional Hospital Saint John, New Brunswick
3Hotel Dieu Hospital Montreal, Quebec
4McGill University, Deparment of Oncology Montreal, Quebec
5Kingston Regional Cancer Centre Kingston
6Toronto Hospital Toronto
7Eli Lilly Canada Inc. Scarborough
8National Cancer Institute of Canada, Clinical Trials Group Kingston, Ontario, Canada
Correspondence to: Dr C. Cripps, Ottawa Regional Cancer Centre, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6. E-mail: ccripps{at}cancercare.on.ca
Background: Metastatic colon cancer is difficult to treat with treatment being palliative and with little effect on survival. This trial has evaluated the effects of LY231514 (Multitargeted antifolate (MTA)) given to previously untreated patients with recurrent or metastatic colorectal carcinoma.
Patients and methods: All patients were required to have a histological diagnosis of colorectal adenocarcinoma with measurable disease and no prior chemotherapy for metastatic disease. Patients had to have had performance status of 0–2, pretreatment absolute granulocyte count of 
1.5 x 109/l and a platelet count of 150 x 109l. Patients received MTA at a dose of 600 mg/m2 by 10 minute infusion on day 1 repeated every 21 days. After the first 9 patients, this dose was reduced down to 500 mg/m2 every 21 days because of toxicity. Doses of MTA were modified depending on nadir counts.
Results: Thirty-two eligible patients were enrolled and twenty-nine were evaluable for response. Three patients did not have repeat radiological testing to determine response because they went off study after only one cycle of treatment due to toxicity. In the 29 evaluable patients, there was 1 complete response, 4 partial responses and 14 patients with stable disease. Response rate was 17.2% (95% confidence intervals: 5.8%–35.8%). All responses occurred in the patients receiving a starting dose of MTA 500 mg/m2. Median time to progression for all eligible patients was 3.3 months. The most common toxicities experienced were mild to moderate fever, lethargy, anorexia, nausea, vomiting, stomatitis, abdominal pain, diarrhea, and skin rash. There was one death due to sepsis.
Conclusion: Single-agent MTA at 500 mg/m2 given every three weeks has modest activity in metastatic colorectal carcinoma.
antifolate, colorectal cancer, phase II trial
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. E. Latz, K. L. Schneck, K. Nakagawa, M. A. Miller, and C. H. Takimoto Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients Clin. Cancer Res., January 1, 2009; 15(1): 346 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohe, Y. Ichinose, K. Nakagawa, T. Tamura, K. Kubota, N. Yamamoto, S. Adachi, Y. Nambu, T. Fujimoto, Y. Nishiwaki, et al. Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2008; 14(13): 4206 - 4212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Socinski, C. Weissman, L. L. Hart, J. T. Beck, J. K. Choksi, J. P. Hanson, D. Prager, M. J. Monberg, Z. Ye, and C. K. Obasaju Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer J. Clin. Oncol., October 20, 2006; 24(30): 4840 - 4847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Wilson Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer Oncologist, October 1, 2006; 11(9): 1018 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hendricksen, P. M.J. Moonen, A. G. van der Heijden, J. Molkenboer-Kuenen, C. A. Hulsbergen-van de Kaa, and J. A. Witjes Potential and Toxicity of Intravesical Pemetrexed: a Preclinical Study in Pigs Clin. Cancer Res., April 15, 2006; 12(8): 2597 - 2601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. X. Ma, P. Steen, K. M. Rowland, R. D. Niedringhaus, T. R. Fitch, J. W. Kugler, D. W. Hillman, E. A. Perez, J. N. Ingle, and A. A. Adjei A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study Ann. Onc., February 1, 2006; 17(2): 226 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Goldberg Advances in the Treatment of Metastatic Colorectal Cancer Oncologist, October 1, 2005; 10(suppl_3): 40 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. X. Ma, S. Nair, S. Thomas, S. J. Mandrekar, D. A. Nikcevich, K. M. Rowland, T. R. Fitch, H. E. Windschitl, S. L. Hillman, S. E. Schild, et al. Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5929 - 5937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Monnerat, T. Le Chevalier, K. Kelly, C. K. Obasaju, J. Brahmer, S. Novello, T. Nakamura, A. M. Liepa, L. Bozec, P. A. Bunn Jr, et al. Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5439 - 5446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Diaz-Rubio New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers Oncologist, June 1, 2004; 9(3): 282 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Scagliotti, D.-M. Shin, H. L. Kindler, M. J. Vasconcelles, U. Keppler, C. Manegold, H. Burris, U. Gatzemeier, J. Blatter, J. T. Symanowski, et al. Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma J. Clin. Oncol., April 15, 2003; 21(8): 1556 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hughes, P. Calvert, A. Azzabi, R. Plummer, R. Johnson, J. Rusthoven, M. Griffin, K. Fishwick, A. V Boddy, M. Verrill, et al. Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma J. Clin. Oncol., August 15, 2002; 20(16): 3533 - 3544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Clarke, R. Abratt, L. Goedhals, M. J. Boyer, M. J. Millward, and S. P. Ackland Phase II trial of pemetrexed disodium (ALIMTA(R), LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer Ann. Onc., May 1, 2002; 13(5): 737 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-R. Hanauske, V. Chen, P. Paoletti, and C. Niyikiza Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors Oncologist, August 1, 2001; 6(4): 363 - 373. [Abstract] [Full Text] [PDF]
|
|